LUX Infusion Unifies Market Access to Fuel Ambitious National Expansion

PLANTATION, Fla. – May 28, 2026 – In a strategic move designed to accelerate its national growth, clinician-led infusion services company LUX Infusion has promoted Dan Teich to the newly created role of Senior Vice President, Market Access. The promotion signals a significant organizational shift, unifying the company's trade relations and managed care operations under a single, cohesive strategy.

The new structure aims to deepen alignment with pharmaceutical manufacturers, specialty distributors, and health plan payors, a critical step as LUX Infusion pushes toward its goal of operating more than 50 infusion locations nationwide. By integrating these two traditionally separate functions, the company is positioning itself to more effectively navigate the complex and often fragmented U.S. healthcare landscape.

"Dan has been an exceptional leader in shaping our trade relationships, and this promotion reflects both his contributions and our confidence in his vision," said Ted Kramm, Chief Executive Officer of LUX Infusion, in a statement. "By unifying trade relations and managed care under his leadership, we are creating a more integrated approach to how we work with our partners, positioning LUX Infusion to deliver greater value across the entire specialty infusion ecosystem."

The Strategic Rationale for Integration

LUX Infusion's decision comes as the specialty infusion market experiences a period of explosive growth. The U.S. home infusion therapy market alone was valued at nearly $20 billion in 2024 and is projected to almost double by 2032, driven by an aging population, the rising prevalence of chronic diseases, and a systemic push toward more cost-effective, out-of-hospital care settings. Ambulatory infusion centers (AICs) are on a similar trajectory, with payers increasingly steering patients toward these freestanding centers, which can offer cost savings of 30-40% compared to hospitals without compromising clinical outcomes.

This booming market, however, is intensely competitive and fraught with operational hurdles. For an infusion provider to succeed and scale, it must master a complex web of relationships. It needs to secure access to high-cost specialty drugs from manufacturers, ensure efficient and reliable delivery through distributors, and negotiate favorable reimbursement contracts with a powerful and consolidated network of insurance companies and pharmacy benefit managers (PBMs).

By placing both trade relations (the manufacturer and distributor side) and managed care (the payer side) under Teich's leadership, LUX Infusion is betting that a unified strategy can break down internal silos and create a more powerful, streamlined approach to partnership management. The goal is to create a frictionless experience not just for patients, but for the partners who are essential to the delivery of care. This integration is designed to enhance contract negotiations, improve supply chain efficiency, and ultimately accelerate the company's ability to open new sites and serve more patients.

An Architect of Access

To lead this critical initiative, LUX Infusion has turned to an executive whose career has been defined by navigating the very complexities this new role seeks to solve. Dan Teich brings over 15 years of diverse leadership experience spanning nearly every corner of the pharmacy and supply chain world.

His resume demonstrates a deep understanding of the financial and operational levers that drive success in specialty healthcare. Prior to joining LUX Infusion, Teich served as Vice President of Health Systems Manufacturer Relations at Cencora (formerly AmerisourceBergen), a giant in specialty drug distribution. There, he led negotiations for specialty and biosimilar contracts on behalf of health systems, giving him an insider's view of how manufacturers and providers connect.

Before that, at M Health Fairview, his impact was twofold. As Vice President of Pharmacy Purchasing and Contracting, he was responsible for a drug spend approaching $1 billion annually, where he drove significant margin improvements through strategic contracting. Perhaps most relevant to his new role, he also served as the Program Manager of Home Infusion and Compounding for the same health system. In that capacity, he grew the home infusion program's revenue by an impressive 240% over four years, demonstrating a direct ability to execute growth strategies in LUX Infusion's core business.

This unique blend of experience—spanning large-scale purchasing, GPO contracting, and hands-on infusion service growth—positions Teich as a credible and effective leader for the company's integrated market access function.

Navigating a Complex Ecosystem

As SVP, Market Access, Teich will be tasked with developing a comprehensive strategy to expand patient access to high-quality infusion care. This involves dismantling the barriers that often stand between a patient and their prescribed therapy.

These barriers are formidable. Providers like LUX Infusion frequently face challenges gaining access to payer networks, which are often dominated by large, vertically integrated competitors like CVS/Coram and Optum. Once in-network, securing adequate and timely reimbursement can become a battle against complex coding requirements, repeated documentation requests, and claim denials.

On the supply side, many new specialty drugs are launched as Limited Distribution Drugs (LDDs), meaning only a select few pharmacies or providers are permitted to dispense them. Gaining access to these LDDs is crucial for offering a comprehensive suite of therapies.

Teich's unified team will be responsible for addressing these challenges holistically. The strategy will involve proving LUX Infusion's value proposition—faster therapy starts, dedicated patient support, and data-driven outcomes—to all stakeholders simultaneously. A strong relationship with a pharmaceutical manufacturer can be leveraged to make a case for inclusion in a payer's network, while robust clinical data can justify reimbursement rates and demonstrate superior patient adherence.

"The convergence of trade relations and managed care under a unified market access function is a natural evolution for LUX Infusion as we scale nationally," Teich stated. "I'm energized by the opportunity to work even more closely with our manufacturer, distribution, and payor partners to remove barriers and ensure patients receive the therapies they need, when and where they need them."

This leadership restructure is a clear signal of LUX Infusion's commitment to building a fully integrated platform. In a market dominated by giants, the company is banking on a smarter, more agile, and deeply integrated approach to partnership as its key to success, allowing it to compete effectively while fulfilling its mission of elevating the infusion experience for patients across the country.